Orphazyme A/S (ORPHA.CO)

DKK 1120.0

(-2.61%)

Operating Income Summary of Orphazyme A/S

Orphazyme A/S's latest annual operating income in 2023 was -27.04 Thousand DKK , up 99.93% from previous year.
Orphazyme A/S's latest quarterly operating income in 2024 Q2 was 847.00 DKK , down 0.0% from previous quarter.
Orphazyme A/S reported an annual operating income of -41.24 Million DKK in 2022, up 93.49% from previous year.
Orphazyme A/S reported an annual operating income of -633.3 Million DKK in 2021, down -4.07% from previous year.
Orphazyme A/S reported a quarterly operating income of 847.00 DKK for 2024 Q2, down 0.0% from previous quarter.
Orphazyme A/S reported a quarterly operating income of -14.2 Million DKK for 2023 Q4, down -56827900.0% from previous quarter.

Annual Operating Income Chart of Orphazyme A/S (2023 - 2015)

Historical Annual Operating Income of Orphazyme A/S (2023 - 2015)

Year	Operating Income	Operating Income Growth
2023	-27.04 Thousand DKK	99.93%
2022	-41.24 Million DKK	93.49%
2021	-633.3 Million DKK	-4.07%
2020	-608.53 Million DKK	-81.14%
2019	-335.95 Million DKK	-45.03%
2018	-231.65 Million DKK	-76.78%
2017	-131.04 Million DKK	-106.3%
2016	-63.52 Million DKK	-19.66%
2015	-53.08 Million DKK	0.0%

Year	Operating Income	Operating Income Growth
2024 Q1	847.00 DKK	100.01%
2024 Q2	847.00 DKK	0.0%
2023 Q4	-14.2 Million DKK	-56827900.0%
2023 Q3	-25.00 DKK	100.0%
2023 Q1	-6417.00 DKK	99.95%
2023 Q2	-12.83 Million DKK	-199900.0%
2023 FY	-27.04 Million DKK	34.43%
2022 Q1	-13.64 Thousand DKK	99.99%
2022 Q4	-13.94 Million DKK	0.0%
2022 FY	-41.24 Million DKK	93.49%
2022 Q2	-27.29 Million DKK	-199900.0%
2021 Q1	-28.67 Thousand DKK	99.99%
2021 FY	-633.3 Million DKK	-4.07%
2021 Q3	-85.4 Thousand DKK	99.98%
2021 Q4	-178.3 Million DKK	-208681.94%
2021 Q2	-408.39 Million DKK	-1424279.19%
2020 Q1	-122.77 Thousand DKK	99.93%
2020 FY	-608.53 Million DKK	-81.14%
2020 Q4	-362.97 Million DKK	-199900.55%
2020 Q3	-181.48 Thousand DKK	99.93%
2020 Q2	-245.55 Million DKK	-199900.81%
2019 Q1	-82.52 Thousand DKK	-35.06%
2019 Q3	-85.44 Thousand DKK	99.95%
2019 Q2	-165.05 Million DKK	-199900.0%
2019 Q4	-170.89 Million DKK	-199900.0%
2019 FY	-335.95 Million DKK	-45.03%
2018 Q3	-61.1 Thousand DKK	-11.66%
2018 Q4	-61.1 Thousand DKK	0.0%
2018 Q2	-54.72 Thousand DKK	0.0%
2018 FY	-231.65 Million DKK	-76.78%
2018 Q1	-54.72 Thousand DKK	-43.63%
2017 Q2	-27.42 Thousand DKK	0.0%
2017 Q3	-38.1 Thousand DKK	-38.94%
2017 Q4	-38.1 Thousand DKK	0.0%
2017 FY	-131.04 Million DKK	-106.3%
2017 Q1	-27.42 Thousand DKK	-66.45%
2016 Q4	-16.47 Thousand DKK	0.0%
2016 FY	-63.52 Million DKK	-19.66%
2016 Q2	-15.28 Thousand DKK	0.0%
2016 Q1	-15.28 Thousand DKK	0.0%
2016 Q3	-16.47 Thousand DKK	-7.78%
2015 FY	-53.08 Million DKK	0.0%

Peer Operating Income Comparison of Orphazyme A/S

Name	Operating Income	Operating Income Difference
ALK-Abelló A/S	666 Million DKK	100.004%
Bavarian Nordic A/S	1.49 Billion DKK	100.002%
Genmab A/S	5.32 Billion DKK	100.001%
Gubra A/S	-49.41 Million DKK	99.945%
Novo Nordisk A/S	102.57 Billion DKK	100.0%
Pharma Equity Group A/S	-25.29 Million DKK	99.893%
Zealand Pharma A/S	-572.23 Million DKK	99.995%